R R

What Is Rybelsus?

Rybelsus is a prescription oral medication containing semaglutide, a glucagon-like peptide-1 receptor agonist. It is approved to improve blood sugar control alongside diet and exercise in adults with type 2 diabetes. It is also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for these events. Rybelsus is taken once daily as an oral tablet. It works by supporting glucose-dependent insulin release, reducing glucagon secretion, and slowing gastric emptying. Rybelsus has two formulations with different tablet strengths that are not interchangeable milligram for milligram. It carries a boxed warning concerning thyroid C-cell tumors.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rybelsus?

Rybelsus is a prescription oral medication containing semaglutide, a glucagon-like peptide-1 receptor agonist. It is approved to improve blood sugar control alongside diet and exercise in adults with type 2 diabetes. It is also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for these events. Rybelsus is taken once daily as an oral tablet. It works by supporting glucose-dependent insulin release, reducing glucagon secretion, and slowing gastric emptying. Rybelsus has two formulations with different tablet strengths that are not interchangeable milligram for milligram. It carries a boxed warning concerning thyroid C-cell tumors.

read more about rybelsus ...

Copy this HTML:

Copy HTML Copied!

How Does Rybelsus Work?

Rybelsus activates glucagon-like peptide-1, or GLP-1, receptors involved in glucose regulation and appetite signaling. When blood glucose levels are elevated, semaglutide increases insulin secretion and reduces glucagon release from the pancreas. It also slows gastric emptying, particularly after meals, which can influence the rate at which glucose enters the bloodstream. These actions help lower blood sugar in adults with type 2 diabetes. Semaglutide can also affect appetite and food intake, but Rybelsus is not the same product as injectable semaglutide formulations approved specifically for weight management. Its cardiovascular benefits have been evaluated separately from its blood glucose-lowering effects.

What Conditions Does Rybelsus Treat?

Rybelsus is approved to improve glycemic control in adults with type 2 diabetes when used with diet and exercise. Another indication is reduction of major adverse cardiovascular events, including cardiovascular death, nonfatal heart attack, or nonfatal stroke, in adults with type 2 diabetes who are at high risk. It is not indicated for type 1 diabetes. Rybelsus is not approved as a dedicated obesity treatment, although weight changes may occur during diabetes treatment. A clinician evaluates HbA1c, cardiovascular risk, kidney function, digestive disorders, and other medications before prescribing it. Patients with diabetic retinopathy may require additional eye monitoring.

How Should Rybelsus Be Taken?

Rybelsus is taken once daily on an empty stomach immediately after waking, with no more than four ounces of plain water. Patients must wait at least 30 minutes before eating, drinking other beverages, or taking other oral medications. Tablets must be swallowed whole. The original formulation begins at 3 mg daily for 30 days, then increases to 7 mg, with a possible increase to 14 mg. The newer formulation begins at 1.5 mg daily for 30 days, then increases to 4 mg, with a possible increase to 9 mg. The formulations have different absorption characteristics and must not be substituted milligram for milligram. The initial doses are for treatment initiation rather than effective maintenance.

What Are the Side Effects and Warnings of Rybelsus?

Common adverse effects include nausea, vomiting, diarrhea, abdominal pain, constipation, and reduced appetite. Rybelsus carries a boxed warning concerning thyroid C-cell tumors observed in rodents. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Other serious risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, and allergic reactions. Hypoglycemia risk increases when combined with insulin or certain insulin-stimulating medications. Diabetic retinopathy complications have been reported with semaglutide treatment. Persistent severe abdominal pain, significant dehydration, or sudden changes in vision require prompt medical evaluation.

Common Questions About Rybelsus

Is Rybelsus the same as semaglutide?

Yes. Rybelsus contains oral semaglutide, a GLP-1 receptor agonist used for type 2 diabetes and cardiovascular risk reduction in specified adults.

Does Rybelsus have different tablet strengths?

Yes. The original formulation uses 3 mg, 7 mg, and 14 mg tablets, while the newer formulation uses 1.5 mg, 4 mg, and 9 mg tablets. They must not be substituted milligram for milligram.

Why must Rybelsus be taken before breakfast?

Food, beverages, and other oral medications can interfere with semaglutide absorption. Rybelsus should be taken with a small amount of plain water, followed by at least 30 minutes before eating or drinking.

Can Rybelsus affect eyesight?

Diabetic retinopathy complications have been reported with semaglutide. Patients with existing diabetic retinopathy may require monitoring, and new vision changes should be evaluated promptly.

References

DailyMed - RYBELSUS (semaglutide) oral tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98. Date Accessed November 4, 2026.

RYBELSUS Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s023lbl.pdf. Date Accessed November 4, 2026.

Semaglutide. MedlinePlus. https://medlineplus.gov/druginfo/meds/a619057.html. Date Accessed November 4, 2026.

Semaglutide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/56843331. Date Accessed November 4, 2026.

Semaglutide Drug Label Information. U.S. Food and Drug Administration. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/378363. Date Accessed November 4, 2026.